
An investigation on behalf of current long-term investors in shares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was announced concerning whether certain directors and officers of AVEO Pharmaceuticals, Inc. breached their fiduciary duties in connection with certain statements made between January 3, 2012 and May 1, 2013 concerning its drug Tivopath or tivozanib.